NCT00506350 - Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults | Biotech Hunter

Enrollment

350

Participants

Timeline

Start Date

August 1, 2007

Primary Completion Date

October 12, 2009

Study Completion Date

October 12, 2009

Conditions

Influenza

Interventions

BIOLOGICAL

Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose

A single dose of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.

BIOLOGICAL

Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses

Two doses of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and Day 21.

Trial Locations (1)

9000

GSK Investigational Site, Ghent